ArticleFrontiers in oncology2023

Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study.

Wen-Jie Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.